Kiadis Pharma Announces Promising Phase II Clinical Trial Results For Reviroc

Main Category: Lymphoma / Leukemia / Myeloma
Also Included In: Cancer / Oncology;  Transplants / Organ Donations;  Clinical Trials / Drug Trials
Article Date: 01 Sep 2007 - 0:00 PDT

email to a friend   printer friendly   opinions  

Oncology focused pharmaceutical development company Kiadis Pharma announced that it has successfully completed a Phase II clinical trial evaluating its product Reviroc(TM). Reviroc is used to eliminate cancer cells from an autologous graft in bone marrow transplantations for end stage blood cancer patients. Data from the clinical study revealed improved overall survival of Reviroc-treated patients. The successful completion of the clinical trial allows Kiadis Pharma to prepare for a Phase III clinical study.

Manja Bouman, CEO, Kiadis Pharma, comments: "We are obviously very pleased with the completion of this Phase II trial of Reviroc. It brings treatment with our product a step closer to patients with end stage blood cancer. Reviroc shares its development platform with two other Kiadis Pharma products: ATIR and Rhitol. The results of this trial therefore mark an important milestone in the development of our entire clinical product pipeline."

In the non-randomized open label study 25 patients, each of whom had reached end stage Non-Hodgkin's lymphoma, were treated in multiple centers in Canada. The objective of the study was to determine the safety of the Reviroc treatment and its ability to eliminate cancer cells from a contaminated graft. Reviroc-treated grafts all showed excellent engraftment, indicating that Reviroc does not negatively impact the graft itself.

The Reviroc clinical trial data was evaluated against a historical patient control group from the Center for International Blood and Marrow Transplant Research (CIBMTR). The results for Reviroc-treated patients were compared with results from the CIBMTR database for patients who had received an autologous transplant without Reviroc. The outcome of this comparison shows that the Reviroc-treated patient group had an 80% chance of survival at 3 years post transplantation, while the CIBMTR control group had a 55% chance of survival at 3 years post transplantation. Based on these promising data, Kiadis Pharma will prepare for a clinical phase III study of Reviroc.

Dr. Denis-Claude Roy at Maisonneuve-Rosemont Hospital in Montreal, commented: "After more then five years of clinical research, we believe that our results demonstrate that Reviroc is able to improve patient survival. This is potentially a breakthrough achievement for patients suffering from Non-Hodgkin's lymphoma as well as their families."

About Reviroc

Reviroc is being developed as a treatment that eliminates blood cancer cells from autologous transplants for patients with end stage blood cancer. An autologous transplant uses the patient's own bone marrow to serve as a graft. Bone marrow transplantations are broadly recognized as a treatment option for patients suffering from blood cancers, such as leukemia and lymphoma. Reviroc has been developed to remove residual tumor cells from the graft.

About Kiadis Pharma

Kiadis Pharma is an oncology focused pharmaceutical development company with four products in different phases of clinical development. The company develops products that offer novel treatment options for terminally ill cancer patients and address high unmet medical needs. Key areas for Kiadis Pharma are clinical indications in blood cancers and solid tumors. Kiadis Pharma is headquartered in the Netherlands with facilities in Groningen, the Netherlands and Montreal, Canada. For more information about Kiadis Pharma, please visit http://www.kiadis.com

Kiadis Pharma
http://www.kiadis.com

• Additional
• References
• Citations